

# Galápagos

## 2023 highlights

We are a pure-play biotechnology company dedicated to developing transformational medicines for more years of life and better quality of life.

### FINANCIAL PERFORMANCE

FULL YEAR 2023 KEY FIGURES (CONSOLIDATED)

€ 239.7  
million

NET REVENUES

€ 414.8  
million

CASH BURN


€ 3.7  
billion

FINANCIAL INVESTMENTS,  
CASH AND  
CASH EQUIVALENTS

€ 241.3  
million

R&D EXPENDITURE

> 21,000 PATIENTS ACROSS EUROPE  
ON JYSELECA®




JYSELECA® NET SALES  
(MILLION EUR)



SCAN FOR MORE DETAILS

### ACHIEVEMENTS



### CELL THERAPY & SMALL MOLECULES PIPELINE

	PROGRAM	TARGET	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	APPROVED
ONCOLOGY	5101	CD19			NHL		
	5201	CD19		CLL/RT			
	5301	BCMA		MM			
		Multiple targets					
IMMUNOLOGY	3667	TYK2			SLE		
	3667	TYK2			DM		
		Multiple targets					

NHL, Non-Hodgkin's lymphoma; CLL, Chronic lymphocytic leukemia, including Richter Transformation (RT); MM, Multiple myeloma, SLE, Systemic lupus erythematosus; DM, Dermatomyositis.

AxSpA, Axial spondyloarthritis; rrNHL, Relapsed/Refractory Non-Hodgkin lymphoma; rrCLL, Relapsed / Refractory Chronic lymphocytic leukemia.

#### Regulatory progress

Investigational New Drug (IND) submission for GLPG5101 in rrNHL

Investigational New Drug (IND) submission for GLPG5201 in rrCLL / RT

#### Trial progress

Phase 2 expansion in U.S. for GLPG5101 in rrNHL (ATALANTA-1)

Phase 2 expansion in EU for GLPG5201 in rrCLL / RT (EUPLAGIA-1)

Phase 1/2 expansion in EU for GLPG5301 in rrMM (PAPILIO-1)

#### Trial updates

GLPG5101 Phase 1/2 in rrNHL (ATALANTA-1)

GLPG5201 Phase 1/2 in rrCLL / RT (EUPLAGIA-1)

GLPG5301 Phase 1/2 in rrMM (PAPILIO-1)

#### Business development

Additional partnerships for CAR-T decentralized manufacturing network

License agreements and/or acquisitions

Research collaborations & equity investments

#### Company headquarters

Generaal De Wittelaan L11 A3  
2800 Mechelen, Belgium  
Tel: +32 15 34 29 00